U2Bio Co (XKRX:221800) EBIT : ₩-350 Mil (TTM As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co EBIT?

U2Bio Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was ₩-17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-350 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. U2Bio Co's annualized ROC % for the quarter that ended in Jun. 2024 was -21.00%. U2Bio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -2.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. U2Bio Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -260.85%.

U2Bio Co EBIT Historical Data

The historical data trend for U2Bio Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co EBIT Chart

U2Bio Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

845.17

307.05

9,182.16

16,152.00

74.47

U2Bio Co Quarterly Data
	Jun22	Mar23	Jun23	Mar24	Jun24
EBIT	1,610.02	321.78	960.96	-332.39	-17.31

Competitive Comparison of U2Bio Co's EBIT

For the Diagnostics & Research subindustry, U2Bio Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U2Bio Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where U2Bio Co's EV-to-EBIT falls into.

U2Bio Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-350 Mil.

U2Bio Co (XKRX:221800) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

U2Bio Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-1403.388 * ( 1 - -1.44% )	/	( (6053.624	+	7506.223)	/ 2 )
=	-1423.5967872	/	6779.9235
=	-21.00 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	47196.143	-	5283.178	-	( 35859.341	-	max(0, 6537.765	-	43205.203	+	35859.341	))
=	6053.624

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	47068.272	-	5129.701	-	( 34432.348	-	max(0, 6372.106	-	43188.125	+	34432.348	))
=	7506.223

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

U2Bio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2024		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-69.248	/	( ( (1358.035 + max(873.313, 0))	+	(1147.038 + max(2169.287, 0)) )	/	2 )
=	-69.248	/	( ( 2231.348	+	3316.325 )	/	2 )
=	-69.248	/	2773.8365
=	-2.50 %

where Working Capital is:

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6230.674	+	727.822	+	277.07)	-	(5283.178	+	0	+	1079.075)
=	873.313

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7645.452	+	727.414	+	80.116999999998)	-	(5129.701	+	0	+	1153.995)
=	2169.287

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

U2Bio Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-349.705	/	134.066
	=	-260.85 %

U2Bio Co EBIT Related Terms

Thank you for viewing the detailed overview of U2Bio Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

U2Bio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Basement 1, 68 Gumaro Songpagu, Seoul, KOR

Website

http://www.u2bio.co.kr

U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co Headlines

No Headlines